| Drug General Information |
| Drug ID |
D0TL3S
|
| Former ID |
DNC009625
|
| Drug Name |
3,4-Benzo-7-acetonyloxy-8-methoxycoumarin
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H14O5
|
| Canonical SMILES |
CC(=O)COC1=C(C2=C(C=C1)C3=CC=CC=C3C(=O)O2)OC
|
| InChI |
1S/C17H14O5/c1-10(18)9-21-14-8-7-12-11-5-3-4-6-13(11)17(19)22-15(12)16(14)20-2/h3-8H,9H2,1-2H3
|
| InChIKey |
KXJLOTAAVRETIT-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Amine oxidase [flavin-containing] B |
Target Info |
Inhibitor |
[1]
|
|---|
| Amine oxidase [flavin-containing] A |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
|
Tryptophan degradation via tryptamine
|
|
Dopamine degradation
|
|
Putrescine degradation III
|
|
Noradrenaline and adrenaline degradationPWY66-401:Superpathway of tryptophan utilization
|
|
Noradrenaline and adrenaline degradation
|
|
Serotonin degradation
|
|
Superpathway of melatonin degradation
|
|
Melatonin degradation II
|
|
KEGG Pathway
|
Glycine, serine and threonine metabolism
|
|
Arginine and proline metabolism
|
|
Histidine metabolism
|
|
Tyrosine metabolism
|
|
Phenylalanine metabolism
|
|
Tryptophan metabolism
|
|
Drug metabolism - cytochrome P450
|
|
Metabolic pathways
|
|
Serotonergic synapse
|
|
Dopaminergic synapse
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholismhsa00260:Glycine, serine and threonine metabolism
|
|
Alcoholism
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
|
5-Hydroxytryptamine degredation
|
|
Dopamine receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Dopamine receptor mediated signaling pathway
|
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
|
PathWhiz Pathway
|
Histidine Metabolism
|
|
Tyrosine Metabolism
|
|
Glycine and Serine Metabolism
|
|
Reactome
|
Norepinephrine Neurotransmitter Release Cycle
|
|
WikiPathways
|
Tryptophan metabolism
|
|
Dopamine metabolism
|
|
Phase 1 - Functionalization of compoundsWP706:SIDS Susceptibility Pathways
|
|
Biogenic Amine Synthesis
|
|
Oxidative Stress
|
|
Phase 1 - Functionalization of compounds
|
|
Neurotransmitter Release Cycle
|
|
Neurotransmitter Clearance In The Synaptic Cleft
|
|
Serotonin Transporter Activity
|
| References |
| REF 1 | J Med Chem. 2008 Nov 13;51(21):6740-51. Epub 2008 Oct 4.Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. |
|---|
